Amyloidosis - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 76 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Amyloidosis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Amyloidosis - Pipeline Review, H2 2014', provides an overview of the Amyloidosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Amyloidosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Amyloidosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Amyloidosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Amyloidosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Amyloidosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Amyloidosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Amyloidosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Amyloidosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Amyloidosis Overview 7
Therapeutics Development 8
Pipeline Products for Amyloidosis - Overview 8
Pipeline Products for Amyloidosis - Comparative Analysis 9
Amyloidosis - Therapeutics under Development by Companies 10
Amyloidosis - Therapeutics under Investigation by Universities/Institutes 11
Amyloidosis - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Amyloidosis - Products under Development by Companies 15
Amyloidosis - Products under Investigation by Universities/Institutes 16
Amyloidosis - Companies Involved in Therapeutics Development 17
GlaxoSmithKline plc 17
Celgene Corporation 18
Onyx Pharmaceuticals, Inc. 19
Bellus Health Inc. 20
ProteoTech, Inc. 21
Auven Therapeutics Management L.L.L.P 22
NeuroPhage Pharmaceuticals, Inc. 23
SOM Biotech SL 24
Amyloidosis - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
eprodisate disodium - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
SOM-0226 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
pomalidomide - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
carfilzomib - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
PTI-110 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
GSK-2315698 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
GSK-2398852 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
GSK-2315698 + GSK-2398852 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
RNAi Oligonucleotides to Inhibit Amyloid Precursor Protein for Amyloidosis - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
NPT-005 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecule for AL Amyloidosis - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Amyloidosis - Recent Pipeline Updates 52
Amyloidosis - Dormant Projects 63
Amyloidosis - Product Development Milestones 64
Featured News & Press Releases 64
May 27, 2014: Auven Therapeutics and Bellus Health Announce Completion of Enrollment in the Phase III Confirmatory Study of Kiacta for the Treatment of AA Amyloidosis 64
May 07, 2014: Auven Therapeutics and BELLUS Health Announce Engagement of Financial Advisor to Explore Sale of KIACTA, an Experimental Drug in Phase III Development for the Treatment of AA Amyloidosis 64
Apr 28, 2014: Tekmira's Partner Presents New Clinical Data for LNP-Enabled Patisiran 65
Apr 23, 2014: Prothena's NEOD001 Demonstrates Encouraging Cardiac Biomarker Responses in Ongoing Phase 1 Study in Patients With Immunoglobulin Light Chain Amyloidosis 66
Mar 18, 2014: Prothena Announces Clinical Data to be Presented at the International Symposium on Amyloidosis 68
Jan 09, 2014: BELLUS Health provides update on KIACTA Phase III orphan drug study 68
Dec 16, 2013: Alnylam Initiates Phase II Clinical Trial with ALN-TTRsc, a Subcutaneously Delivered RNAi Therapeutic Targeting Transthyretin in Development for the Treatment of TTR-Mediated Amyloidosis 69
Nov 25, 2013: Alnylam Earns $7 Million Milestone Payment from Genzyme for Phase II Success with Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin for the Treatment of TTR-Mediated Amyloidosis 70
Nov 11, 2013: Alnylam Receives Fast Track Designation for Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin for the Treatment of TTR-Mediated Amyloidosis 71
Nov 10, 2013: Alnylam Reports Positive Phase II Data for Patisiran, an RNAi Therapeutic Targeting Transthyretin for the Treatment of TTR-Mediated Amyloidosis, and Initiates Phase III Trial 72
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 76
Disclaimer 76

List of Tables
Number of Products under Development for Amyloidosis, H2 2014 8
Number of Products under Development for Amyloidosis - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Investigation by Universities/Institutes, H2 2014 16
Amyloidosis - Pipeline by GlaxoSmithKline plc, H2 2014 17
Amyloidosis - Pipeline by Celgene Corporation, H2 2014 18
Amyloidosis - Pipeline by Onyx Pharmaceuticals, Inc., H2 2014 19
Amyloidosis - Pipeline by Bellus Health Inc., H2 2014 20
Amyloidosis - Pipeline by ProteoTech, Inc., H2 2014 21
Amyloidosis - Pipeline by Auven Therapeutics Management L.L.L.P, H2 2014 22
Amyloidosis - Pipeline by NeuroPhage Pharmaceuticals, Inc., H2 2014 23
Amyloidosis - Pipeline by SOM Biotech SL, H2 2014 24
Assessment by Monotherapy Products, H2 2014 25
Assessment by Combination Products, H2 2014 26
Number of Products by Stage and Target, H2 2014 28
Number of Products by Stage and Mechanism of Action, H2 2014 30
Number of Products by Stage and Route of Administration, H2 2014 32
Number of Products by Stage and Molecule Type, H2 2014 34
Amyloidosis Therapeutics - Recent Pipeline Updates, H2 2014 52
Amyloidosis - Dormant Projects, H2 2014 63